Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

There is a considerable variability in the level of molecular responses achieved with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences could result from variable therapy adherence. Eighty-seven patients with chronic-phase CML treated with imatinib 400 mg/d for a me...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2010-05, Vol.28 (14), p.2381-2388
Hauptverfasser:	MARIN, David, BAZEOS, Alexandra, PALIOMPEIS, Christos, LATHAM, Victoria, FORONI, Letizia, MOLIMARD, Mathieu, REID, Alistair, REZVANI, Katy, DE LAVALLADE, Hugues, GUALLAR, Cristina, GOLDMAN, John, KHORASHAD, Jamshid S, MAHON, Francois-Xavier, ELIASSON, Lina, MILOJKOVIC, Dragana, BUA, Marco, APPERLEY, Jane F, SZYDLO, Richard, DESAI, Ritti, KOZLOWSKI, Kasia
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use ATP Binding Cassette Transporter, Subfamily B ATP Binding Cassette Transporter, Subfamily B, Member 1 - genetics Benzamides Biological and medical sciences Chemotherapy Cytogenetic Analysis Drug Monitoring - instrumentation Female Fusion Proteins, bcr-abl - genetics Gene Expression Regulation, Leukemic Hematologic and hematopoietic diseases Humans Imatinib Mesylate Kaplan-Meier Estimate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Logistic Models Male Medical sciences Medication Adherence Micro-Electrical-Mechanical Systems - instrumentation Middle Aged Mutation Octamer Transcription Factor-1 - genetics ORIGINAL REPORTS Pharmacology. Drug treatments Piperazines - pharmacokinetics Piperazines - therapeutic use Polymorphism, Genetic Proportional Hazards Models Protein Kinase Inhibitors - pharmacokinetics Protein Kinase Inhibitors - therapeutic use Pyrimidines - pharmacokinetics Pyrimidines - therapeutic use Risk Assessment Risk Factors RNA, Messenger - metabolism Time Factors Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!